Medicine
Atorvastatin calcium propylene glycol solvate 40 mg tablet
Atorvastatin calcium propylene glycol solvate 40 mg tablet is a generic prescription medicine for oral use, made by 15 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Atorvastatin calcium propylene glycol solvate
- Brand
- Sold under the generic name
- Strength
- 40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 10 blister pack, 30 tablets, 500 tablets and 32 more
- Manufacturers
- ApotexVangard LabsA-S Medication SolutionsCardinal HealthProficient RxRemedyrepackMajor PharmaceuticalsNorthStar RxAmerican Health PackagingAvPAK15 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 May 2012
- Identifiers
- RxCUI 259255, 617311, 617310 +1DailyMed set ID e74278b6-31fc-48d4-97b7-ba500e9e15fb, 5412835b-27c6-461f-97b9-b5bf03afe7f2, 1b8c55ef-160d-42df-95d1-c008f1182e3e +15NDC 0904-6292, 43063-453, 50090-6441 +15Application ANDA090548
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 blister pack in 1 carton / 10 tablet, film coated in 1 blister pack | 60505-2580-0 | Apotex | 29 May 2012 |
| 30 tablet, film coated in 1 bottle | 60505-2580-3 | Apotex | 29 May 2012 |
| 500 tablet, film coated in 1 bottle | 60505-2580-5 | Apotex | 29 May 2012 |
| 4000 tablet, film coated in 1 bottle | 60505-2580-7 | Apotex | 29 May 2012 |
| 1000 tablet, film coated in 1 bottle | 60505-2580-8 | Apotex | 29 May 2012 |
| 90 tablet, film coated in 1 bottle | 60505-2580-9 | Apotex | 29 May 2012 |
| 10 blister pack in 1 bag / 1 tablet, film coated in 1 blister pack | 55154-4166-0 | Cardinal Health | 31 October 2014 |
| 10 blister pack in 1 bag / 1 tablet, film coated in 1 blister pack | 55154-6646-0 | Cardinal Health | 9 July 2013 |
| 10 blister pack in 1 bag / 1 tablet, film coated in 1 blister pack | 55154-7628-0 | Cardinal Health | 31 October 2014 |
| 30 tablet, film coated in 1 bottle | 50090-6440-0 | A-S Medication Solutions | 17 April 2023 |
| 90 tablet, film coated in 1 bottle | 50090-6440-1 | A-S Medication Solutions | 17 April 2023 |
| 100 tablet, film coated in 1 bottle | 50090-6440-2 | A-S Medication Solutions | 17 April 2023 |
| 90 tablet, film coated in 1 bottle | 50090-6441-0 | A-S Medication Solutions | 17 April 2023 |
| 100 blister pack in 1 box, unit-dose / 1 tablet, film coated in 1 blister pack | 68084-099-01 | American Health Packaging | 19 September 2013 |
| 50 blister pack in 1 box, unit-dose / 1 tablet, film coated in 1 blister pack | 50268-095-15 | AvPAK | 28 June 2016 |
| 50 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0904-6292-06 | Major Pharmaceuticals | 31 October 2014 |
| 100 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 0904-6292-61 | Major Pharmaceuticals | 31 October 2014 |
| 90 tablet, film coated in 1 bottle | 16714-175-01 | Northstar RX | 1 August 2021 |
| 1000 tablet, film coated in 1 bottle | 16714-175-03 | Northstar RX | 1 August 2021 |
| 30 tablet, film coated in 1 bottle, plastic | 82868-029-30 | Northwind Health | 30 November 2023 |
| 30 tablet, film coated in 1 bottle, plastic | 43063-453-30 | PD-Rx Pharmaceuticals | 29 May 2012 |
| 30 tablet, film coated in 1 bottle | 63187-109-30 | Proficient Rx | 1 August 2015 |
| 60 tablet, film coated in 1 bottle | 63187-109-60 | Proficient Rx | 1 August 2015 |
| 90 tablet, film coated in 1 bottle | 63187-109-90 | Proficient Rx | 1 August 2015 |
| 1000 tablet, film coated in 1 bottle | 82009-003-10 | Quallent | 23 November 2021 |
| 90 tablet, film coated in 1 bottle, plastic | 70518-1322-1 | Remedyrepack | 25 July 2018 |
| 30 tablet, film coated in 1 blister pack | 70518-1322-2 | Remedyrepack | 25 July 2018 |
| 60 tablet, film coated in 1 blister pack | 70518-1322-5 | Remedyrepack | 17 April 2026 |
| 30 tablet, film coated in 1 blister pack | 87441-013-01 | Unit Dose Solutions | 8 June 2026 |
| 15 tablet, film coated in 1 blister pack | 0615-8008-05 | Vangard Labs | 6 November 2018 |
| 7 tablet, film coated in 1 blister pack | 0615-8008-07 | Vangard Labs | 6 November 2018 |
| 14 tablet, film coated in 1 blister pack | 0615-8008-14 | Vangard Labs | 13 December 2022 |
| 28 tablet, film coated in 1 blister pack | 0615-8008-28 | Vangard Labs | 16 April 2024 |
| 6 blister pack in 1 box, unit-dose / 5 tablet, film coated in 1 blister pack | 0615-8008-30 | Vangard Labs | 12 November 2018 |
| 30 tablet, film coated in 1 blister pack | 0615-8008-39 | Vangard Labs | 6 November 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Atorvastatin calcium propylene glycol solvate
Clinical summary
Atorvastatin calcium propylene glycol solvate is an HMG-CoA reductase inhibitor indicated to reduce the risk of myocardial infarction (MI), stroke, among other approved uses. MedsAcross supplies Atorvastatin calcium propylene glycol solvate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Atorvastatin calcium propylene glycol solvateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ATORVASTATIN CALCIUM prescribing information (Apotex) · U.S. National Library of Medicine, DailyMed
Need Atorvastatin calcium propylene glycol solvate 40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.